Lumena Pharmaceuticals

General Information

We are a biopharmaceutical company focused on the development and commercialization of novel products for rare cholestatic liver diseases and serious metabolic disorders, such as nonalcoholic steatohepatitis, or NASH, where there is a high unmet medical need. We are developing two clinical-stage product candidates, LUM001 and LUM002, that inhibit the apical sodium-dependent bile acid transporter, or ASBT, which is primarily responsible for recycling bile acids from the intestine to the liver.

Employees: 17
Founded: 2011
Contact Information
Address 12531 High Bluff Drive, Suite 110, San Diego, CA 92130, US
Phone Number (858) 461-0694
Web Address
View Prospectus: Lumena Pharmaceuticals
Financial Information
Market Cap
Revenues $0 mil (last 12 months)
Net Income $-15.0 mil (last 12 months)
IPO Profile
Symbol LIVR
Exchange NASDAQ
Shares (millions): 0.0
Price range $0.00 - $0.00
Est. $ Volume $75.0 mil
Manager / Joint Managers Citigroup/ Cowen and Company/ Leerink Partners
CO-Managers -
Expected To Trade:
Status: Withdrawn
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change